



sYnAbs

Singular Antibodies



Why SynAbs?



SynAbs, singular mAbs

- ✓ Stable and productive homohybridoma thanks to:
 - **proprietary rat IR983 fusion cell line**
 - **proprietary guinea pig Syn2.2 fusion cell line**
- ✓ Host variation offers **different antibody responses**
- ✓ Access to the **lymph nodes**
- ✓ **Higher** affinity & **higher** specificity mAbs
- ✓ No special growth media, Serum Free adaptation

SynAbs, a complete catalogue

- ✓ Secondary antibodies
- ✓ Isotype controls
- ✓ Anti-species Ig (re: Animal Health)
 - Targeting the **complete mouse, rat and human immunoglobulin repertoires**
 - **Extensively validated** in different techniques
 - **Distributed by BioRad, Thermo Fisher,...**
 - Packaging : single specificities, cocktails
 - Labeling : FITC, BIOT, HRP, custom

SynAbs in a nutshell

- ✓ Spin-off UCL/CHEX
- ✓ Location : Gosselies
- ✓ Team : 10 scientists
- ✓ Revenues : 750k€, consistently growing.



SynAbs, one-stop-shop solution



- ✓ **Tailor-made services**, from antigen synthesis through mAbs manufacturing to chimerization, humanization and fragments design
- ✓ **A large secondary antibodies catalog**, distributed by worldwide leaders
- ✓ **Multi-species immunisation** for high success rate, cost and time savings!

Success is on the cards!

- A highly specific mAb to PTM Histone
- A unique mAb on the market
- A company which can enjoy renewed success



« We chose to launch one 'hard' program with SynAbs in order to develop an anti-PTM antibody. Indeed, there is no existing available monoclonal antibody for that given modification as of today.

We are delighted with the collaboration with Synabs!

We got a purified antibody with a high specificity to the very methyl group !

They know what they are talking about and have considerable experience with antibody production. They are also very flexible and the communication flow is efficient as well. As this program is a success, we will initiate new ones shortly. »

Gaetan Michel, VolitionRx, CEO



Success is on the cards!

- From preclinical to clinical development for IL-34
- Benefit from RD Biotech/SynAbs synergy
- Humanization and chimerization programs



The
University
Of
Sheffield.

« For a new therapeutic, we were looking for a one-stop-shop solution offering the entire set of tools from preclinical to clinical development.

Thanks to synergetic effect, the couple RD Biotech – SynAbs has been able to first generate a mAb mouse with strong inhibitory effect, then a rat monoclonal antibody against mouse-IL34 showing the same potency effect.

The latter has been successfully chimerized by RD Biotech to be used in prolonged in-vivo studies in mice, and the former will be soon humanized by this same team for human clinical trials! »

Dominique Heymann, Professor of Bone Oncology, University of Sheffield

Success is on the cards!

- **A new mAb against joint health degradation peptides**
- **Benefit from rat-LOU expertise**
- **Multiple programs partnership**



« Our project on joint health degradation biomarker was not on the right track and so we were considering a smart way to bounce back and forth.

SynAbs was the solution.

They're highly specialized in mAb field, have proved to be a proactive provider, with high commitment to build a long-term partnership. »

Pr. Yves Henrotin, CEO & Founder, Artialis

Success is on the cards!

- High affinity mAbs for infectious targets
- Multi-species immunization schedule
- Perfect matched pair mAbs for sandwich ELISA



« Coris had identified two promising targets and wished to ultimately develop sandwich ELISA to quantify these biomarkers.

The unique approach of SynAbs with multi-species immunization has allowed the generation of high affinity mAbs both in rat and mouse.

These two mAbs are now the very basis of our sandwich immuno-assay ! »

Thierry Leclipteux, CEO, Coris Bioconcept

Success is on the cards!

- Unique mAb for steroid
- Benefit from flexible and reliable partner
- From mgr to grs custom bioproduction



« As a leading in-vitro diagnostic provider to the clinical laboratory market, IDS is compelled to continuously rely on strong preferred partners who commit to high quality standards.

For a project involving the development of innovative immunoassays against a particular steroid, SynAbs rapidly came to the conclusion that only rat-LOU species could deliver the expected outcomes.

This small molecule project has become a huge success ! »

Mhammed Bougoussa, R&D Manager, Immunodiagnostic Systems